(NASDAQ: SXTP) 60 Degrees Pharmaceuticals's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 56.52%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 101.51%.
60 Degrees Pharmaceuticals's earnings in 2025 is -$8,299,494.On average, 4 Wall Street analysts forecast SXTP's earnings for 2025 to be -$9,001,101, with the lowest SXTP earnings forecast at -$8,648,116, and the highest SXTP earnings forecast at -$9,265,839. On average, 4 Wall Street analysts forecast SXTP's earnings for 2026 to be -$22,439,953, with the lowest SXTP earnings forecast at -$21,559,955, and the highest SXTP earnings forecast at -$23,099,952.
In 2027, SXTP is forecast to generate -$1,967,682 in earnings, with the lowest earnings forecast at -$1,890,518 and the highest earnings forecast at -$2,025,555.